Episode 417: Pharmacology 101: Oncolytic Viral Therapy
From The ONS Podcast · · 35 min
This plays from the publisher's own server. We do not host a copy.
Description
"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of pharmacy at Mayo Clinic Alix School of Medicine in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about oncolytic viral therapy.
Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 29, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge about the use of oncolytic viruses to treat cancer.
Episode Notes - Complete this evaluation for free NCPD.
- ONS Podcast™ episodes: - Pharmacology 101 series
- Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role
- Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs
- Episode 273: Updates in Chemotherapy and Immunotherapy
- ONS Voice articles: - Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy
- Oncolytic Virus Kills Tumor Cells While Supporting T Cells
- What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma
- Clinical Journal of Oncology Nursing articles: - Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative
- Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting
- Oncology Nursing Forum article: Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma
- ONS book: Guide to Cancer Immunotherapy (second edition)
- ONS clinical practice resource: Safe Handling of Oncolytic Viruses
- ONS Huddle Card: Immunotherapy
- Association of Community Cancer Centers (ACCC) (https://www.accc-cancer.org/)
- Drugs@FDA
- Hematology/Oncology Pharmacy Association (HOPA) (https://www.hoparx.org/)
- Network for Collaborative Oncology Development and Advancement (NCODA) (https://ncoda.org/)
- Patient Education Sheets (https://patienteducationsheets.com/)
To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/).
To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Highlights From This Episode "[Oncolytic viruses] can have direct lysis to the tumor cells themselves, or they can cause immunogenic activation. They release tumor-associated antigens and then proinflammatory signals, so think of T cells, natural killer cells, those sorts of things, that can convert to immunologically cold tumors. Those are tumors that are immune silenced into hot tumors which are now immune activated. By doing that, they recruit those T cells and other cells to the area to attack both the primary tumors. But that's also thought to be how they work on distant or noninjected sites as well. This immunomodulatory capacity has led to the reclassification of oncolytic viruses as a form of…